As per a report from Transparency Market Research Inc., the global market for quality control in the manufacturing of CGT (cell and gene therapies) is anticipated to reach a value of $2.8 billion by the year 2031. It is estimated to undergo substantial growth at an annual compound growth rate (CAGR) of 24.6% from 2023 to 2031. In contrast, the market is foreseen to be worth $463.1 million by the conclusion of 2023.
With the proliferation of research and development activities in cell and gene therapy, there is an escalating requirement for robust quality control measures to ensure the safe and effective production and quality of these groundbreaking therapies.
The research points out that advancements in analytical technologies, along with the integration of cutting-edge technologies such as automation, robotics, and artificial intelligence (AI) into quality control processes, have considerably bolstered the industry’s capacity to scrutinize, characterize, and guarantee the high quality of cell and gene therapy products. This advancement is facilitating the feasibility of comprehensive quality evaluations, and as a result, it is expected to drive up market demand, according to the report’s authors.
Furthermore, the report underscores the growing demand for quality control measures in this field, driven by the need for adequate quality control of these therapies and the rising trend toward personalized medicine.
Data from the report indicates that potency testing, serving as an analytical method, reigns supreme in the global cell and gene therapy manufacturing quality control sector during the forecast period.
Regarding regional market dominance, North America is poised to claim the largest share of the cell and gene therapy manufacturing quality control market between 2023 and 2031. This is attributed to the robust presence of research, biotechnology, and pharmaceutical industries in the region, coupled with increased government funding for life sciences research and biotechnology, contributing to market growth.
The Asia Pacific region is also expected to secure a significant market share, spurred by heightened demand for innovative treatment options, which has driven the development as well as manufacturing of cell, gene therapies throughout the area.
Prominent players in the market landscape include bioMérieux SA, Charles River Laboratories International, Lonza Group AG, Merck KGaA, Thermo Fisher Scientific, Inc., Eurofins Scientific S.E., and F. Hoffmann-La Roche Ltd.